Science

Revolutionizing delivery
across the blood-brain barrier.

Our Platform: TRACER

Reaching CNS targets once thought unreachable.

Voyager’s TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) capsid discovery platform is a broadly applicable, RNA-based screening platform that enables rapid discovery of AAV capsids with robust penetration of the blood-brain barrier and enhanced central nervous system (CNS) tropism in multiple species, including non-human primates (NHPs).

Learn More About TRACER

Non-Viral Approaches

Multiple modalities to treat neurological diseases.

The Voyager team has expertise in the discovery and development of monoclonal antibodies as well as in receptor-mediated non-viral delivery to the central nervous system.

“I love how we all get to collaborate, even though we are on different teams.”

Gretchen Rivera, Research Associate II, Vector Genome

Voyager_publications_img

Recent Publications & Presentations

ADPD 2025:
VY1706, A BBB-Penetrant, IV-delivered AAV Gene Therapy Provides Broad and Robust CNS tau Lowering in Tauopathy Mouse Models and Non-Human Primate

Discrimination of Anti-tau Antibodies Targeting Different tau Epitopes by a P301S Mouse Hippocampal Seeding Model of Tauopathy

International Symposium on ALS/MND 2024:
Intravenous Delivery of AAV Gene Therapy for the Treatment of SOD1-ALS Provides Broad SOD1 Lowering in NHP

View All

Our Pipeline

Transforming breakthrough science into medicines.

Partnerships

Our allies in realizing the potential of neuro-genetic medicines

Partner_Logo_White_Alexion

Partner_Logo_White_Neurocrine

Partner_Logo_White_Novartis